10-Q - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

424B3 - Kairos Pharma, LTD. (0001962011) (Filer)

SCHEDULE 13G/A - Kairos Pharma, LTD. (0001962011) (Subject)

10-Q - Kairos Pharma, LTD. (0001962011) (Filer)

10-K/A - Kairos Pharma, LTD. (0001962011) (Filer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

3 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

Company makes important progress in 2025 and looks ahead into 2026 Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below. To our valued Kairos Pharma Shareholders, This year, Kairos has been focused on executing its Phase 2 randomized clinical trial of ENV105 in combination with apalutamide in patients with advanced metastatic prostate cancer. The study is designed to evaluate the safety, tolerability, and early signs of efficacy of ENV105, a CD105 antagonist, in men whose disease has progre

Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society Medical Oncologists meeting in Berlin, Germany. An interim efficacy analysis from the ongoing trial with ENV-105, a first-in-class CD105 antagonist, is being tested for safety and early efficacy in men with metastatic pr

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present at the European Society for Medical Oncology (ESMO) Congress. Kairos's presentation, titled, "Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer" will take place in Berlin, Germany on October 17–21, 2025. Prostate cancer remains one of the most diagnosed cancers in men, with over a million new cases annually in the U.S. alone. Resistance to androgen-targeted therapies represents a major clinical challenge

Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety data Company to host virtual KOL discussion today to provide additional perspective on data and the Company's lead program Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Kairos Pharma is hosting a virtual KOL (key opinion leader) event to provide perspectives on this data at 5 p.m. ET / 2 p.m. PT today. Interested pa

Event to feature principal investigators from the trial Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company's interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Interested participants can sign-up to receive the webcast link here. "The safety results of the trial are an important catalyst as we prepare for the announcement of our interim efficacy

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference which takes place September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain. Dr. Reckamp's presentation, "Combination of Osimertinib and Carotuximab for Advanced, EFGR-Mutated Non-Small Cell Lung Cancer Patients," focuses on combination therapy of ENV105 with osimertinib for the treatment of non-small cell lung cancer. More information on the

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel. Presentation Date:  September 5, 2025 Time:  Available on-demand starting at 7:00 AM Eastern Time Webcast Link: https://journey.ct.events/view/567df3a2-9eaf-4575-bb61-3cdabd42346f A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A r

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. Kairos Pharma will participate in on-on-one meetings and present at the meeting which will be available virtually and hosted on the kairospharma.com website. John Yu, MD, CEO and Chairman, will be hosting one-on-one meetings during the meeting September 8-10. To register for one-on-one meetings with management at The Lotte New York Palace Hotel in New York City please registe

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim safety analysis of the trial demonstrated that ENV-105, a first-in-class CD105 antagonist, was well tolerated when combined with standard of care hormone therapy, apalutamide, from the first ten enrolled patients. Thus far, there have been no dose-limiting toxicities or unexpected adverse events reported to date. In addition, the treatment-related side effects were manageable with stand

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," the study authors presented their findings that demonstrated KROS 101's capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mecha